Cargando…
Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia
No specific therapy is available for COVID-19. We report the effectiveness and adverse effects of triple therapy with hydroxychloroquine, azithromycin, and ciclesonide in patients with COVID-19 pneumonia. The clinical condition of the patients improved within 5 days in response to the therapy.
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534751/ https://www.ncbi.nlm.nih.gov/pubmed/33054978 http://dx.doi.org/10.1016/j.jmii.2020.09.003 |